Try our Advanced Search for more refined results
February 12, 2016
McGlothin v. CTI BioPharma Corp et al
Case Number:
2:16-cv-00216
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bernstein Litowitz
- Breskin Johnson
- Dorsey & Whitney
- Federman & Sherwood
- Gainey McKenna
- Glancy Prongay
- Jones Day
- Keller Rohrback
- Lieff Cabraser
- O'Melveny & Myers
- Perkins Coie
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
September 05, 2017
CTI BioPharma Settles Investor Testing Info Row For $20M
CTI BioPharma Corp. and its executives will pay $20 million to a proposed class of investors for allegedly withholding information about patient deaths during clinical trials for a myelofibrosis drug, which led to a stock drop when the U.S. Food and Drug Administration stopped the trials, the investors told a Washington federal court on Friday.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login